Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet Oncology.[1] …
Continue reading →
The final analysis of the Selenium and Vitamin E Cancer Prevention Trial (SELECT) indicated that vitamin E increased the risk of developing prostate cancer in otherwise healthy men by 17% when compared to placebo. The results of the study were …
Continue reading →
For men with locally advanced or high-risk prostate cancer, treatment with a combination of radiation therapy and hormone therapy appears to be more effective than hormone therapy alone. These results were published in The Lancet. Locally advanced prostate cancer refers to cancer that has spread through the prostate capsule but not to distant sites in [...]
The results of a large, randomized trial suggest that taking daily vitamin E supplements may increase a man’s risk of prostate cancer. These results were published in the Journal of the American Medical Association. Prostate cancer is the most commonly diagnosed type of cancer (other than skin cancer) in US men. Although many prostate cancers [...]
Delivering a shorter course of external-beam radiation therapy—with higher doses of radiation given at each visit—appears to be as effective for prostate cancer as the conventional approach to external-beam radiation therapy. These results were presented at the 53rd Annual Meeting of the American Society for Radiation Oncology (ASTRO). Prostate cancer is the most commonly diagnosed [...]
Among men with metastatic, hormone-refractory prostate cancer that has previously been treated with Taxotere® (docetaxel), Zytiga® (abiraterone) reduced fatigue in addition to improving overall survival. These results were presented at the 2011 European Multidisciplinary Cancer Congress. Prostate cancer is a hormonally sensitive disease that can often be controlled for long periods with androgen-deprivation therapy (ADT). [...]
In a Phase III clinical trial, the investigational drug radium-223 chloride (Alpharadin) improved overall survival among prostate cancer patients with bone metastases. These results were presented at the 2011 European Multidisciplinary Cancer Congress. Metastatic cancer refers to cancer that has spread to distant sites in the body. Several types of cancer—including prostate cancer—have a tendency [...]
Among men with prostate cancer that has stopped responding to hormonal therapy, the bone drug Xgeva™ (denosumab) delayed the spread of cancer to the bones. These results were presented at the 2011 European Multidisciplinary Cancer Conference. Androgen deprivation therapy (ADT) often plays an important role in the treatment of prostate cancer. ADT slows or stops [...]
Information about a man’s baseline characteristics and prostate cancer treatment plan can help predict erectile function after treatment. These results were published in the Journal of the American Medical Association. Prostate cancer is the most commonly diagnosed type of cancer (other than skin cancer) in US men. Most men will survive a diagnosis of early-stage [...]
The U.S. Food and Drug Administration (FDA) has expanded the approval of Prolia® (denosumab) to include treatment of bone loss among breast cancer patients treated with aromatase inhibitor therapy and prostate cancer patients treated with androgen deprivation therapy for non-metastatic cancer. Treatment is intended to increase bone mass among patients at high risk of fracture. [...]
